

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ABSTRACT (in English)	iv
ABSTRACT (in Thai)	vi
TABLE OF CONTENTS	viii
LIST OF TABLES	xiii
LIST OF FIGURES	xv
ABBREVIATIONS	xvi
CHAPTER 1 INTRODUCTION	
1. Rational	1
2. Purposes of the study and hypothesis	3
3. Advantages of the study	4
CHAPTER 2 LITERATURE REVIEWS	
1. Lung cancer	5
1.1 Epidemiology and incidence	5
1.2 Causes	6
1.3 Symptoms	8

1.4 Types	10
1.5 Stages	11
1.6 Treatment	12
2. Chemotherapy and new agent targeted therapy	13
2.1 Response of chemotherapy treatment	15
2.2 Benefit of chemotherapy	15
2.3 Side effects of chemotherapy	16
2.4 Common chemotherapy regimens in lung cancer and adverse effects	17
2.5 Effects of chemotherapy on cardiorespiratory fitness	19
2.5.1 Mechanism of pulmonary function change and previous studies	19
2.5.2 Mechanism of cardiovascular system change and previous studies	21
3. Effect of chemotherapy on QoL in lung cancer patients	23
Summary and conceptual framework	25
4. The measurement of the study	27
4.1 Pulmonary function test	27
4.2 Six Minute Walk Test (6MWT)	28
4.3 Quality of life questionnaire in lung cancer	30

CHAPTER 3 METHODS

1. Participants	32
2. Study design	33
3. Instruments	34
4. Outcome measures	34
5. Procedures	37
6. Statistical analysis	40
7. Reliability of measurements	40
8. Location	41

CHAPTER 4 RESULTS

1. Reliability of measurements	42
1.1 Six Minute Walk Test (6MWT)	42
1.2 Pulmonary Function Tests (PFTs)	42
2. Demographic data of participants	44
3. Outcome measurements	45
3.1 Exercise capacity	45
3.2 Cardiovascular variables response to 6MWT	46
3.3 Pulmonary function tests	49
3.4 Quality of life items	51
3.4.1 QLQ C-30	51
3.4.2 LC-13	52

CHAPTER 5 DISCUSSION


1. Exercise capacity	54
2. Cardiovascular variables response to 6MWT	57
2.1 Pre-heart rate	58
2.2 Post-heart rate and percent changed of maximum heart rate	58
2.3 Percent of oxygen saturation	59
2.4 Blood pressure	59
2.5 Dyspnea level and leg fatigue level	60
3. Pulmonary function test	60
4. Quality of life questionnaires (EORCE QLQ C-30 and LC-13)	63
5. Conclusion	67
6. Clinical application and future study	68
7. Limitations and suggestions	69

REFERENCES	70
-------------------	----

APPENDICES

APPENDIX A Calculation of sample size	81
APPENDIX B Contraindications to exercise testing	83
APPENDIX C Questionnaire forms	85
APPENDIX D Data collection form	91

APPENDIX E Information for participants	93
APPENDIX F Consent form	100
APPENDIX G Certificate of approval	102
CURRICULUM VITAE	103



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF TABLES

Table	Page
1 Common chemotherapy regimens in lung cancer and adverse effects	17
2 Characteristics data of all participants for reliability study of 6MWT	42
3 Characteristics data of all participants for reliability study of PFTS	43
4 The intraclass correlation coefficients (ICC _(3,1)) of measurements	43
5 Characteristics data of subjects	45
6 Six Minute Walk Distance (Mean ± SD) (n=12), within group comparision using Repeated measured ANOVA	46
7 Cardiovascular variables responded to 6MWT (Mean ± SD) (n=12), ^a = significant difference from pre-1 st course of chemotherapy, ^b = significant difference from post-2 nd course of chemotherapy, within group comparison using repeated measured ANOVA	47
8 Pulmonary function tests (Mean ± SD) (n=12), ^a = significant difference from pre-1 st course of chemotherapy, within group comparison using repeated measured ANOVA	50

9	Quality of life items [QLQ C-30] (Median) (n=12), within group comparison using Friedman Test, post hoc test using Wilcoxon Signed Ranks Test	51
10	Quality of life items [LC-13] (Median) (n=12), ^a = significant difference from pre-1 st chemo, ^b = significant difference from pre-2 nd chemo, within group comparison using Friedman Test, post hoc test using Wilcoxon Signed Ranks Test	53
11	The comparison of previous studies and the present study on exercise capacity.	55
12	The comparison of many previous studies and present study on PFTs.	61
13	The comparison of many previous studies and present study on QoLs.	64

LIST OF FIGURES

Figure	Page
1 The conceptual framework of the study (the vicious cycle of chemotherapy)	27
2 Flowchart all of the procedure of participants through study	39
3 Six Minute Walk Distance (Mean \pm SD)	46
4 Post-heart rate (Mean \pm SD)	48
5 Post-fatigue (Mean \pm SD)	49
6 PEF _R % _{predicted} (Mean \pm SD)	50

ABBREVIATIONS

NSCLC	Non-Small Cell Lung Cancer
SCLC	Small cell lung cancer
QoL	Quality of life
PFTs	Pulmonary function tests
FEV ₁	Forced expiratory volume in one second
FVC	Forced vital capacity
FEV ₁ /FVC	The ratio of FEV ₁ /FVC
PEFR	Peak expiratory flow rate
FEF _{25-75%}	Forced expiratory flow at 25-75 % of FVC
6MWT	Six minute walk test
6MWD	Six minute walk distance